| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/01/2001 | WO2001007655A1 Antisense modulation of shp-2 expression |
| 02/01/2001 | WO2001007637A2 Conditionally controlled, attenuated hiv vaccine |
| 02/01/2001 | WO2001007628A2 Human synthetases |
| 02/01/2001 | WO2001007627A1 Drosophila recombination-associated protein and methods for use |
| 02/01/2001 | WO2001007625A2 Ehrlichia canis genes and vaccines |
| 02/01/2001 | WO2001007612A2 Receptors and associated proteins |
| 02/01/2001 | WO2001007611A2 Novel polynucleotides and method for the use thereof |
| 02/01/2001 | WO2001007604A1 Isolated peptide of the horny layer and use thereof |
| 02/01/2001 | WO2001007602A2 Oligonucleotides for inhibiting the expression of human eg5 |
| 02/01/2001 | WO2001007595A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | WO2001007594A1 Antisense modulation of mekk1 expression |
| 02/01/2001 | WO2001007568A2 Muscle cells and their use in cardiac repair |
| 02/01/2001 | WO2001007486A1 A biodegradable polycation composition for delivery of an anionic macromolecule |
| 02/01/2001 | WO2001007476A1 26 human prostate and prostate cancer associated proteins |
| 02/01/2001 | WO2001007475A1 Novel peptides |
| 02/01/2001 | WO2001007469A2 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 02/01/2001 | WO2001007461A1 Antisense modulation of mekk5 expression |
| 02/01/2001 | WO2001007457A1 Antisense modulation of pten expression |
| 02/01/2001 | WO2001007456A1 Antisense modulation of jun n-terminal kinase kinase-1 expression |
| 02/01/2001 | WO2001007066A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | WO2001007065A2 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 02/01/2001 | WO2001007059A1 Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| 02/01/2001 | WO2001006989A2 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 02/01/2001 | WO2001006988A2 Super-active porcine growth hormone releasing hormone analog |
| 02/01/2001 | WO2000066722B1 Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof |
| 02/01/2001 | WO2000066720A3 The use of adeno-associated virus (aav) deliver cytoprotective genes |
| 02/01/2001 | WO2000061736A3 Recombinant and mutant marek's disease virus |
| 02/01/2001 | WO2000053742A3 Polynucleotides and proteins encoded thereby |
| 02/01/2001 | WO2000053733A3 Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof |
| 02/01/2001 | WO2000044906A3 GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI) |
| 02/01/2001 | WO2000037493A3 Type iii secretion system antigens from bordetella pertussis |
| 02/01/2001 | WO2000009668A9 Engraftable human neural stem cells |
| 02/01/2001 | WO1999065461A9 Cationic amphiphile micellar complexes |
| 02/01/2001 | WO1999041376A9 Retinoblastoma protein complexes and retinoblastoma interacting proteins |
| 02/01/2001 | DE19934458A1 Composition for treating pigmentation disorders, e.g. vitiligo, containing the protein DCoH, or related nucleic acids, antibodies or antisera |
| 02/01/2001 | DE10022687A1 Gene-transfer vector containing an enhancer-promoter, useful for prevention or treatment of tumors, is able to enter normal tissue to prevent metastasis |
| 02/01/2001 | CA2696819A1 Ghrelin related peptides |
| 02/01/2001 | CA2396591A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 02/01/2001 | CA2380317A1 Human synthetases |
| 02/01/2001 | CA2380270A1 26 human prostate and prostate cancer associated proteins |
| 02/01/2001 | CA2380226A1 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | CA2380192A1 Oligonucleotides for inhibiting the expression of human eg5 |
| 02/01/2001 | CA2380178A1 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 02/01/2001 | CA2379802A1 Drosophila recombination-associated protein and methods for use |
| 02/01/2001 | CA2379801A1 Receptors and associated proteins |
| 02/01/2001 | CA2379777A1 Isolated peptide of the horny layer and use thereof |
| 02/01/2001 | CA2379659A1 Antisense modulation of pten expression |
| 02/01/2001 | CA2378953A1 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 02/01/2001 | CA2378643A1 Muscle cells and their use in cardiac repair |
| 02/01/2001 | CA2378462A1 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | CA2378403A1 Novel polynucleotides and method for the use thereof |
| 02/01/2001 | CA2375650A1 Ehrlichia canis genes and vaccines |
| 01/31/2001 | EP1072680A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/31/2001 | EP1071823A2 Novel mutations in the (freac3 )gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis |
| 01/31/2001 | EP1071806A2 Materials and methods for gene therapy |
| 01/31/2001 | EP1071805A2 Adenoviral vectors for treating disease |
| 01/31/2001 | EP1071804A1 Use of triplex structure dna sequences for transferring nucleotide sequences |
| 01/31/2001 | EP1071794A1 A method for inhibiting tumor invasion or spreading in a subject |
| 01/31/2001 | EP1071783A2 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis |
| 01/31/2001 | EP1071778A2 Srebp-2-deficient cell lines |
| 01/31/2001 | EP1071777A2 Human nucleic acid sequences of normal uterus tissue |
| 01/31/2001 | EP1071776A2 Human nucleic acid sequences of normal bladder tissue |
| 01/31/2001 | EP1071775A2 Human nucleic acid sequences of endometrium tumour tissue |
| 01/31/2001 | EP1071774A2 Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |
| 01/31/2001 | EP1071771A2 Gene encoding syntaxin interacting protein |
| 01/31/2001 | EP1071768A1 Delivery of therapeutic proteins via implantation of genetically modified cells in the omentum |
| 01/31/2001 | EP1071764A1 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN $g(a) v?-SUBUNIT EXPRESSION |
| 01/31/2001 | EP1071758A1 Porcine adenovirus type 3 genome |
| 01/31/2001 | EP1071753A2 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| 01/31/2001 | EP1071752A1 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| 01/31/2001 | EP1071749A1 Novel lrsg protein and nucleic acid molecules and uses therefor |
| 01/31/2001 | EP1071715A2 TRANSFERRIN RECEPTOR GENES OF $i(MORAXELLA) |
| 01/31/2001 | EP1071709A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 01/31/2001 | EP1071699A1 Enhanced antisense modulation of icam-1 |
| 01/31/2001 | EP1071698A1 Nucleic acid sequences and proteins associated with aging |
| 01/31/2001 | EP1071696A1 Programmed cell death and caspase-12 |
| 01/31/2001 | EP1071485A2 Revascularization apparatus having coaxial channeling and injection means |
| 01/31/2001 | EP1071472A1 Peptides for efficient gene transfer |
| 01/31/2001 | EP1071470A1 COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN DELIVERY TO ANTIGEN PRESENTING CELLS $i(IN VIVO) |
| 01/31/2001 | EP1071459A1 Methods to provoke anti-cancer immune responses |
| 01/31/2001 | EP1071458A1 Humanized antibody and uses thereof |
| 01/31/2001 | EP1071447A1 Treatment for diabetes |
| 01/31/2001 | EP1071445A2 Therapeutic angiogenic factors and methods for their use |
| 01/31/2001 | EP1071434A1 Cnre binding factors and uses thereof |
| 01/31/2001 | EP1071377A1 Needleless administration of polynucleotide formulations |
| 01/31/2001 | EP1071325A1 Compositions and methods for antigen-specific vaccination |
| 01/31/2001 | CN1282372A Mammalian sytokine-like polypeptide-10 |
| 01/31/2001 | CN1282338A A DNA molecule encoding mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof |
| 01/31/2001 | CN1281899A Human tumor related gene in region of sub-band 3 of band 3 of zone 1 of human chromosome No.17 |
| 01/31/2001 | CN1281699A Preparation of EIA-specicial medicinal compound for making medicine for resisting heat-cervical tumor and its application |
| 01/30/2001 | US6180766 Nucleosides and oligonucleotides containing boron clusters |
| 01/30/2001 | US6180613 AAV-mediated delivery of DNA to cells of the nervous system |
| 01/30/2001 | US6180403 Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| 01/30/2001 | US6180387 Nucleotide sequence coding an enzymatic polypeptide; for the detection of bactericides and batericidal agonist and antagonists which prevent bacterial infection |
| 01/30/2001 | US6180384 Compounds |
| 01/30/2001 | US6180380 Cloning of a new member of the serine threonine kinase family |
| 01/30/2001 | US6180379 Eukaryotic transport protein; for utilization in the ubiquination and degradation of cell cycle polypeptides |
| 01/30/2001 | US6180371 Modified factor VIII |
| 01/30/2001 | US6180362 Peptides which inhibit ras protein activity, their preparation and use |
| 01/30/2001 | US6180353 Nucleotide sequences associated with suppression of transcription binding protein associated with apoptosis; for the treatment and prevention defects associated with apoptosis |